ClinicalTrials.gg
CompletedNCT01768572Updated Jun 26, 2017Results posted

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

A Phase 3 interventional study of sarilumab SAR153191 (REGN88) and tocilizumab in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 78 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
7th of 22
202 · median 88
Started
2013
with 1 other
Phase 3
9 of 22
1 open now
Registered
10th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 10th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.

Read the detailed description

Total study duration was up to 34 weeks: Screening up to 28 days, treatment phase of 24 weeks, and post-treatment follow-up of 6 weeks.

After completion of the treatment phase of this study, participants were eligible to enter a long term safety study (LTS11210) for active treatment with SAR153191 (REGN88).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of RA was, according to the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010 Rheumatoid Arthritis Classification Criteria with ≥ 3 months disease duration

ACR Class I-III functional status, was based on the 1991 revised criteria. Moderate-to-severely active RA. Anti-TNF therapy failures, was defined as participants with an inadequate clinical response was defined by the investigator, after being treated for at least 3 consecutive months, and/or intolerance to at least 1 TNF-antagonist, resulting in or requiring their discontinuation. TNF-antagonists were include, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab pegol

Continuous treatment with one or a combination of non-biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 consecutive weeks prior to screening and on a stable dose(s) for at least 6 consecutive weeks prior to screening:

  • Methotrexate - 10 to 25 milligram/week orally or parenteral (or per local labelling requirements if the dose range differs)
  • Leflunomide - 10 to 20 mg orally daily
  • Sulfasalazine (SSZ) - 1000 to 3000 mg orally daily
  • Hydroxychloroquine (HCQ) - 200 to 400 mg orally daily

Exclusion criteria

Exclusion criteria:

Participants \<18 years of age. Use of parenteral or intra-articular corticosteroids within 4 weeks prior to screening

Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks prior to screening

Past history of, or current, or inflammatory systemic or localized joint disease(s) other than RA

History of juvenile idiopathic arthritis or arthritis onset prior to age 16. Severe systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome

Participation in any clinical research study that evaluated an drug or therapy within 5 half-lives or 60 days of the Screening Visit, whichever was longer

Participants with active tuberculosis or latent tuberculosis infection. Prior or current history of interstitial lung disease. Prior treatment with anti-interleukin (IL) -6 or anti-IL-6R therapies, including but not limited to tocilizumab or sarilumab

Treatment with anti-TNF agents, as follows:

  • Etanercept: within 28 days prior to randomization
  • Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to randomization

Treatment with RA-directed biologic agents with non- TNF-α antagonist mechanisms without adequate as follows:

  • Anakinra: within 28 days prior to randomization
  • Abatacept: within 42 days prior to randomization
  • Rituximab or other cell depleting agent: Within 6 months prior to randomization or until total lymphocyte count and CD 19+ lymphocyte count were normalized, or whichever was longer

Prior treatment with a janus kinase (JAK) inhibitor (eg, tofacitinib). Participants with a history of invasive opportunistic infection. Prior or current history of , including lymphoproliferative diseases, other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit

Prior or current history of other significant concomitant illness(es) that, according to Investigator's judgement, was adversely affect the participant's participation in the study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Sarilumab 150 mg q2w

    Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.

    Drug: sarilumab SAR153191 (REGN88) · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: intravenous placebo

  • Experimental
    Sarilumab 200 mg q2w

    Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.

    Drug: sarilumab SAR153191 (REGN88) · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: intravenous placebo

  • Active comparator
    Tocilizumab q4w

    Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.

    Drug: tocilizumab · Drug: hydroxychloroquine · Drug: methotrexate · Drug: sulfasalazine · Drug: leflunomide · Drug: subcutaneous placebo

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

  • Pharmaceutical form: solution Route of administration: intravenous

  • Dispensed according to local practice.

  • Dispensed according to local practice.

  • Dispensed according to local practice.

  • Dispensed according to local practice.

  • Drugsubcutaneous placebo

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Drugintravenous placebo

    Pharmaceutical form: solution Route of administration: intravenous

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. All adverse events that occurred from the first dose of the study drug administration up to 60 days after the end of treatment visit were considered as TEAEs. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. A summary of SAEs, all other non-serious AEs, regardless of causality, are reported in AE section.

    Time frame: Up to 211 days

07

Results

Posted Jun 26, 2017

Participant flow

The study was conducted at 78 centers in 19 countries. A total of 389 participants were screened between 25 March 2013 and 02 April 2014, 187 of whom were screen failures. Screen failures were mainly due to failure to meet inclusion and exclusion criteria.

Participant flow — Overall Study
MilestoneSarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4w
Started4951102
Completed403996
Not completed9126
Withdrew: Adverse event784
Withdrew: Lack of efficacy131
Withdrew: Other, not due to an adverse event111

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. All adverse events that occurred from the first dose of the study drug administration up to 60 days after the end of treatment visit were considered as TEAEs. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. A summary of SAEs, all other non-serious AEs, regardless of causality, are reported in AE section.

Time frame:
Up to 211 days
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsSarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4w
Any TEAE333668
Any treatment-emergent SAE137
Any TEAE leading to death001
Any TEAE leading to discontinuation684

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 211) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab 150 mg q2w—1/49 (2%)33/49 (67.3%)
Sarilumab 200 mg q2w—3/51 (5.9%)36/51 (70.6%)
Tocilizumab q4w—7/102 (6.9%)66/102 (64.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4w
Deep vein thrombosisVascular disorders1/490/510/102
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/490/510/102
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/490/510/102
Urinary tract infectionInfections and infestations0/491/510/102
Atrial fibrillationCardiac disorders0/491/510/102
Transaminases increasedInvestigations0/491/510/102
ErysipelasInfections and infestations0/490/511/102
Septic shockInfections and infestations0/490/511/102
NeutropeniaBlood and lymphatic system disorders0/490/511/102
TremorNervous system disorders0/490/511/102
Most frequent other events
Showing 10 of 145
Most frequent other events
EventSarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4w
NeutropeniaBlood and lymphatic system disorders6/498/513/102
NasopharyngitisInfections and infestations6/493/514/102
Accidental overdoseInjury, poisoning and procedural complications1/493/519/102
Urinary tract infectionInfections and infestations4/491/516/102
Injection site erythemaGeneral disorders4/494/511/102
Upper respiratory tract infectionInfections and infestations2/491/517/102
NauseaGastrointestinal disorders1/491/517/102
GastroenteritisInfections and infestations3/490/511/102
HypercholesterolaemiaMetabolism and nutrition disorders2/491/516/102
DizzinessNervous system disorders1/493/514/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
Mean54.8 ± 12.151.7 ± 13.150.4 ± 13.051.8 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
Female413982162
Male8122040
Duration of rheumatoid arthritis (RA) since diagnosis
Duration of rheumatoid arthritis (RA) since diagnosis(years)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
Mean13.59 ± 8.2410.45 ± 7.5710.84 ± 8.9111.41 ± 8.48
RA functional class
RA functional class(participants)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
I1041630
II253362120
III14142452
IV0000
Health Assessment Questionnaire Disability Index (HAQ-DI)
Health Assessment Questionnaire Disability Index (HAQ-DI)(units on a scale)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
Mean1.63 ± 0.661.71 ± 0.601.78 ± 0.631.72 ± 0.63
Disease Activity Score for 28 Joints- C-reactive protein (DAS28-CRP)
Disease Activity Score for 28 Joints- C-reactive protein (DAS28-CRP)(score on scale)Sarilumab 150 mg q2wSarilumab 200 mg q2wTocilizumab q4wTotal
Mean5.85 ± 0.925.88 ± 0.975.91 ± 1.015.89 ± 0.97
08

Study locations

78 sites
  • Investigational Site Number 840152
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840151
    Colorado Springs, Colorado 80903, United States
  • Investigational Site Number 840153
    Aventura, Florida 33180, United States
  • Investigational Site Number 840033
    Fort Lauderdale, Florida 33334, United States
  • Investigational Site Number 840048
    Miami, Florida 33155, United States
  • Investigational Site Number 840155
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840013
    Wheaton, Maryland 20902, United States
  • Investigational Site Number 840154
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840150
    Lansing, Michigan 48910, United States
  • Investigational Site Number 840062
    Reading, Pennsylvania 19611, United States
  • Investigational Site Number 840038
    Austin, Texas 78705, United States
  • Investigational Site Number 840022
    Dallas, Texas 75235, United States
  • Investigational Site Number 840156
    Dallas, Texas 75246, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 032006
    Caba, C1015ABO, Argentina
  • Investigational Site Number 032010
    Ramos Mejia, B1704ETD, Argentina
  • Investigational Site Number 032013
    Rosario, S200PBJ, Argentina
  • Investigational Site Number 032015
    San Fernando, Argentina
  • Investigational Site Number 032004
    San Miguel De Tucuman, 4000, Argentina
  • Investigational Site Number 032005
    Tucuman, 4000, Argentina
  • Investigational Site Number 056010
    Leuven, 3000, Belgium
  • Investigational Site Number 076001
    Curitiba, 80060-240, Brazil
  • Investigational Site Number 076030
    Sao Jose Do Rio Preto, 15090-000, Brazil
  • Investigational Site Number 203009
    Liberec, 46063, Czechia
  • Investigational Site Number 203011
    Praha 2, 12850, Czechia
  • Investigational Site Number 203010
    Praha 4, 140 00, Czechia
  • Investigational Site Number 233010
    Tallinn, 10138, Estonia
  • Investigational Site Number 233002
    Tallinn, 13419, Estonia
  • Investigational Site Number 246001
    Helsinki, 00290, Finland
  • Investigational Site Number 246010
    Riihimäki, 11120, Finland
  • Investigational Site Number 348014
    Budapest, 1027, Hungary
  • Investigational Site Number 348022
    Budapest, 1036, Hungary
  • Investigational Site Number 348021
    Esztergom, 2500, Hungary
  • Investigational Site Number 348016
    Kistarcsa, 2143, Hungary
  • Investigational Site Number 348009
    Szolnok, 5000, Hungary
  • Investigational Site Number 348015
    Szombathely, 9700, Hungary
  • Investigational Site Number 376010
    Haifa, 31096, Israel
  • Investigational Site Number 376011
    Tel Aviv, 64239, Israel
  • Investigational Site Number 380002
    Firenze, 50141, Italy
  • Investigational Site Number 380005
    Genova, 16132, Italy
  • Investigational Site Number 484008
    Durango, 34080, Mexico
  • Investigational Site Number 484035
    Leon, 37000, Mexico
  • Investigational Site Number 484009
    Merida, 97000, Mexico
  • Investigational Site Number 484001
    México, D.F., 11850, Mexico
  • Investigational Site Number 484036
    Zapopan, 44280, Mexico
  • Investigational Site Number 528010
    Amsterdam, 1056 AB, Netherlands
  • Investigational Site Number 528001
    Leiden, 2333 ZA, Netherlands
  • Investigational Site Number 578010
    Kristiansand, 4604, Norway
  • Investigational Site Number 578006
    Tønsberg, 3105, Norway
  • Investigational Site Number 616019
    Bydgoszcz, 85-168, Poland
  • Investigational Site Number 616054
    Bytom, 41-902, Poland
  • Investigational Site Number 616030
    Lublin, 20-090, Poland
  • Investigational Site Number 616031
    Warszawa, 01-518, Poland
  • Investigational Site Number 616017
    Warszawa, 02-653, Poland
  • Investigational Site Number 642006
    Braila, 810019, Romania
  • Investigational Site Number 642020
    Bucharest, 020125, Romania
  • Investigational Site Number 642010
    Bucharest, Romania
  • Investigational Site Number 642021
    Bucuresti, 010584, Romania
  • Investigational Site Number 642001
    Bucuresti, 010976, Romania
  • Investigational Site Number 642022
    Targoviste, 130083, Romania
  • Investigational Site Number 643017
    Kemerovo, 650066, Russian Federation
  • Investigational Site Number 643020
    Moscow, 115404, Russian Federation
  • Investigational Site Number 643001
    Moscow, 115522, Russian Federation
  • Investigational Site Number 643002
    Moscow, 117997, Russian Federation
  • Investigational Site Number 643031
    Moscow, 121374, Russian Federation
  • Investigational Site Number 643030
    Moscow, 125284, Russian Federation
  • Investigational Site Number 643032
    St-Petersburg, 191186, Russian Federation
  • Investigational Site Number 724020
    Barcelona, 08035, Spain
  • Investigational Site Number 724021
    Santander, 39008, Spain
  • Investigational Site Number 724022
    Sevilla, 41010, Spain
  • Investigational Site Number 752004
    Malmö, 205 02, Sweden
  • Investigational Site Number 752002
    Uppsala, 751 85, Sweden
  • Investigational Site Number 826004
    Doncaster, DN2 5LT, United Kingdom
  • Investigational Site Number 826006
    Edinburgh, EH4 2XU, United Kingdom
  • Investigational Site Number 826001
    Leeds, LS7 4SA, United Kingdom
  • Investigational Site Number 826002
    London, E11 1NR, United Kingdom
  • Investigational Site Number 826005
    Southampton, SO16 6YD, United Kingdom
  • Investigational Site Number 826025
    Wigan, WN6 9EP, United Kingdom
09

References and documents

Publications

  • Rehberg M, Giegerich C, Praestgaard A, van Hoogstraten H, Iglesias-Rodriguez M, Curtis JR, Gottenberg JE, Schwarting A, Castaneda S, Rubbert-Roth A, Choy EHS; MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. 2021 Dec;8(4):1661-1675. doi: 10.1007/s40744-021-00361-5. Epub 2021 Sep 14. Erratum In: Rheumatol Ther. 2021 Dec;8(4):1921-1922. doi: 10.1007/s40744-021-00389-7. PubMed 34519964 ↗
  • Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):405-416. doi: 10.1002/psp4.12534. Epub 2020 Jun 20. PubMed 32453485 ↗
  • Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 May 1;58(5):849-858. doi: 10.1093/rheumatology/key361. PubMed 30590833 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 8 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2013
First posted
Jan 15, 2013
Start
Mar 2013
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results delay requested
Oct 7, 2015
Results first posted
Jun 26, 2017
Last update
Jun 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01768572
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 15, 2013
Start date
Mar 2013
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Jun 26, 2017
Last update
Jun 26, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion